

Human Whole Exome Sequencing

1. Sample Requirements

| Sample Type | Amount (Qubit®) | Volume | Concentration | Purity (NanoDrop™) |
|------------------------|-----------------|---------|---------------|--|
| Genomic DNA | ≥ 300 ng | ≥ 15 μL | ≥ 20 ng/μL | OD260/280=1.8-2.0; no degradation, no contamination |
| cfDNA/ctDNA | ≥ 30 ng | - | - | Fragments should be in multiples of 170 bp, no genomic contamination |
| Genomic DNA from *FFPE | ≥ 500 ng | - | - | Fragments should be longer than 1000 bp |

^{*}FFPE: Formalin-fixed-paraffin-embedded

2. Sequencing Parameters

| Platform | Illumina NovaSeq 6000 | | |
|------------------------------|---|--|--|
| Read length | Paired-end 150 bp | | |
| Recommended sequencing depth | For Mendelian disorder/rare disease: effective sequencing depth above 50 \times (6 G); For tumor sample: effective sequencing depth above 100 \times (12 G) | | |
| Data quality | Guaranteed ≥ 85% bases with Q30 or higher | | |
| **Turnaround time | 22 working days from verification of sample quality to data releasing without bioinformatic analysis | | |

^{**}Turnaround time varies depending on the project volume.

3. Data Analysis Contents

Standard Analysis

Data quality control: filtering reads containing adapter or with low quality

Alignment with reference, statistics of sequencing depth and coverage

SNP and InDel calling, annotation and statistics

Somatic variant detection (only apply for tumor-normal paired samples) SNP calling, annotation and statistics InDel calling, annotation and statistics CNV calling, annotation and statistics



| | Methods | | |
|-------------------|---------------------------------|--|--|
| Advanced analysis | Cancer | Screening for Predisposing Genes (feasible if only normal samples are provided) | |
| | | Mutational Spectrum & Mutational Signature | |
| | Driver gene analysis | Identification of Known Driver Genes | |
| | | Significantly Mutated Gene & Pathway Analysis | |
| | | Mutation Relation Test of Significantly Mutated Genes | |
| | | Identification of Driver Genes Based on Mutation Clustering Bias | |
| | | Identification of Driver Somatic CNVs | |
| | | Mutation Site Displaying | |
| | Tumor heterogeneity analysis | Tumor Purity & Ploidy Estimation | |
| | | Intra-tumor Heterogeneity Analysis | |
| | | Tumor Evolution Analysis (One normal and at least 3 tumor samples from the same patient are needed) | |
| | | Tumor Neoantigen Identification | |
| | Monogenic disease | Candidate Variant Filtration | |
| | | Analysis under dominant / recessive model | |
| | | Linkage Analysis | |
| | | Region of Homozygosity Analysis (ROH) | |
| | Polygenic disease | Candidate Variant Filtration | |
| | | Analysis under dominant / recessive model | |
| | | Linkage Analysis | |
| | | Region of Homozygosity Analysis (ROH) | |
| | | De novo SNV/InDel Analysis | |